Annika Kasprzak
Overview
Explore the profile of Annika Kasprzak including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
20
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jager P, Biermann B, Liebers N, Schulz F, Baermann B, Twarock S, et al.
EJHaem
. 2025 Mar;
6(2):e70012.
PMID: 40041662
Background: Allogeneic hematopoietic stem cell transplantation (allo-SCT) is a key treatment for hematologic malignancies, but donor selection impacts outcomes. Results: In a cohort of 152 patients undergoing allo-SCT from 2012...
2.
Schulz F, Roggenbuck C, Kundgen A, Kasprzak A, Nachtkamp K, Jager P, et al.
Ann Hematol
. 2025 Jan;
104(1):231-239.
PMID: 39794531
As median age of patients with acute myeloid leukemia is 72 years, older patients continue to be a vulnerable cohort representing significant challenges in clinical practice. Patient-specific comorbidities as well...
3.
Steinmetz T, Totzke U, Kasprzak A, Schmitz S, Gattermann N, Germing U
Ann Hematol
. 2024 Aug;
103(12):4913-4930.
PMID: 39174754
Since the late 1980s, patient registries have played a pivotal role in the elucidation of rare diseases. For myelodysplastic syndromes (MDS), they revealed the disease actually to be diverse rather...
4.
Kasprzak A, Andresen J, Nachtkamp K, Kundgen A, Schulz F, Strupp C, et al.
Cancers (Basel)
. 2024 Feb;
16(4).
PMID: 38398198
Despite notable advancements in infection prevention and treatment, individuals with hematologic malignancies still face the persistent threat of frequent and life-threatening complications. Those undergoing chemotherapy or other disease-modifying therapies are...
5.
Schulz F, Jager P, Tischer J, Fraccaroli A, Bug G, Hausmann A, et al.
Cancers (Basel)
. 2024 Feb;
16(3).
PMID: 38339283
Up to 50% of patients with high-risk myeloid malignancies die of relapse after allogeneic stem cell transplantation. Current sequential conditioning regimens like the FLAMSA protocol combine intensive induction therapy with...
6.
Silzle T, Blum S, Kasprzak A, Nachtkamp K, Rudelius M, Hildebrandt B, et al.
Cancers (Basel)
. 2023 Jul;
15(14).
PMID: 37509235
The absolute monocyte count (AMC) is associated with mortality in a variety of medical conditions. Its prognostic impact in myelodysplastic syndromes (MDSs) is less well studied. Therefore, we investigated its...
7.
Jager P, Rautenberg C, Kaivers J, Kasprzak A, Geyh S, Baermann B, et al.
Sci Rep
. 2023 Jul;
13(1):10774.
PMID: 37402862
Patients with acute myeloid leukemia (AML) and nucleophosmin 1 gene mutations (NPM1) show a favorable prognosis with chemotherapy (CT) in the absence of negative prognostic genetic abnormalities. Between 2008 and...
8.
Kasprzak A, Nachtkamp K, Gattermann N, Germing U
Cancers (Basel)
. 2022 Apr;
14(8).
PMID: 35454847
Prognostic stratification in patients with myelodysplastic syndrome (MDS) relies on a number of key factors. Combining such patient-related and disease-related prognostic parameters into useful assessment tools remains a challenge. The...
9.
Hybrid or Mixed Myelodysplastic/Myeloproliferative Disorders - Epidemiological Features and Overview
Kuendgen A, Kasprzak A, Germing U
Front Oncol
. 2021 Dec;
11:778741.
PMID: 34869027
The WHO-category Myelodysplastic/Myeloproliferative neoplasms (MDS/MPNs) recognizes a unique group of clonal myeloid malignancies exhibiting overlapping features of myelodysplastic as well as myeloproliferative neoplasms. The group consists of chronic myelomonocytic leukemia...
10.
Kasprzak A, Kaivers J, Nachtkamp K, Haas R, Kobbe G, Gattermann N, et al.
Int J Environ Res Public Health
. 2021 Jul;
18(14).
PMID: 34300079
The heterogeneous group of myelodysplastic syndromes (MDS) needs an individualized and patient-tailored therapeutic approach. Consensus-based guidelines for diagnosis and treatment provide a basis for clinical decision making. MDS guidelines are...